FDA Approves Darolutamide for mCSPC Prostate Cancer Pancreatic 3 Mins Read On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved Darolutamide for de novo metastatic castration-sensitive prostate cancer…
